Neuroblastoma Survival Rate: What the Statistics Mean, Stage by Stage, and What Changes Them

A parent once described the moment this way: the oncologist drew a chart on the back of a lab printout, and every line of it seemed to end in a percentage. Eighty-something for this group. Fifty-something for that one. She said the numbers felt like a verdict before anyone had explained what they were measuring.

Neuroblastoma is unusual among cancers because it behaves so differently from one child to the next. In some infants it shrinks and disappears without a single dose of treatment. In an older child with the same diagnosis on paper, it can be one of the hardest cancers in pediatric medicine. One name, two entirely different diseases, and one survival figure that averages them together in a way that tells any single family very little.

This article pulls those numbers apart. What a five-year rate actually counts, why doctors speak in risk groups rather than stages, which features of a child and a tumor move the odds, and where the evidence is honest about its own limits.

What does a neuroblastoma survival rate actually measure?

A five-year survival rate is a head count taken years after the fact. Researchers gather every child diagnosed within a certain window, follow them for five years, and report the share still living. Nothing in that figure says a child stops being at risk at year five, and nothing in it predicts what will happen to the next child through the door.

Two quirks matter for neuroblastoma in particular. The first is lag. To publish a five-year rate, the children counted must have been diagnosed at least five years earlier, and most large registries take longer than that to close their books. The number a family reads today usually describes children treated a decade ago, before some of the approaches now considered standard for high-risk disease were widely used. The National Cancer Institute (NCI) notes that survival in high-risk neuroblastoma has improved with the addition of immunotherapy, an improvement that older registry figures only partly capture.

The second quirk is averaging. Neuroblastoma statistics are often quoted as a single overall number, roughly eight in ten children surviving five years according to the NCI. That figure blends infants whose tumors regress on their own with older children fighting widespread disease. It is accurate as an average and almost meaningless as a forecast for any one child. The useful numbers live one level down, in the risk groups, which is where the rest of this article goes.

Is neuroblastoma a curable cancer?

For most children, yes, though the honest answer depends heavily on which form of the disease is being discussed. The NCI describes low-risk and intermediate-risk neuroblastoma as having excellent outcomes, with five-year survival above 95% and around 90 to 95% respectively. Many of these children are treated with surgery alone or with a limited course of chemotherapy, and some infants are simply observed while the tumor matures or shrinks.

High-risk neuroblastoma is a different conversation. Here the NCI and the Cleveland Clinic put long-term survival at roughly half of children, a figure that has climbed over the past two decades but remains far below the rest of pediatric oncology. Doctors treating this form tend to use careful language. They talk about achieving remission, about the risk of relapse, and about the years of follow-up needed before anyone uses a word like cured.

Why so much variation inside one diagnosis? Neuroblastoma arises from immature nerve cells that, in a developing fetus, are supposed to mature into parts of the sympathetic nervous system or die off. In some children the tumor cells seem to remember that program and finish maturing on their own. In others, particularly when specific genetic changes are present, the cells have lost that ability entirely and grow relentlessly. The word neuroblastoma covers both, which is why no single answer about curability fits every child.

How common is neuroblastoma, and who gets it?

Neuroblastoma is the most common cancer diagnosed in the first year of life and the most common solid tumor in children that starts outside the brain, according to the NCI. Even so, it is rare in absolute terms. The NCI estimates roughly 650 to 700 new cases each year in the United States, about 6% of all childhood cancers.

Age is the defining feature. The median age at diagnosis is about 17 to 18 months, and the NCI reports that roughly 90% of cases are found before age 5. Diagnosis in a school-age child or teenager happens, but it is uncommon and, as later sections explain, tends to come with a more difficult outlook.

The tumor most often begins in the adrenal glands, the small hormone-producing organs sitting on top of each kidney, or along the chain of sympathetic nerve tissue running beside the spine in the chest, abdomen, or pelvis. About half of children already have disease that has spread at diagnosis, most often to bone, bone marrow, liver, or lymph nodes, per the NCI.

Families almost always ask whether they missed something or did something to cause it. The evidence says no on both counts. The Mayo Clinic notes that no lifestyle or environmental exposure has been convincingly linked to neuroblastoma. A small minority of cases, about 1 to 2% according to the NCI, run in families through inherited gene changes, and those families are usually offered genetic counseling.

Neuroblastoma survival rate by risk group: the numbers

Modern treatment protocols sort each child into a risk group before treatment begins. The sorting uses the tumor’s extent, the child’s age, and several biological features of the tumor cells examined under the microscope and in the laboratory. The resulting groups predict outcome far better than stage alone, which is why every major reference now reports survival this way.

Risk group	Who typically falls here	Approximate 5-year survival
Low risk	Localized tumors, most infants, favorable biology; includes many stage 4S/MS infants	More than 95% (NCI)
Intermediate risk	Larger or regionally spread tumors without high-risk biology; some infants with metastatic disease	Roughly 90 to 95% (NCI)
High risk	Metastatic disease in children older than 18 months, or any stage with MYCN gene amplification	Roughly 50%, improving in recent cohorts (NCI, Cleveland Clinic)

The gap between the bottom and top rows is what makes neuroblastoma statistics so treacherous when quoted without context. A child in the low-risk group has one of the best prognoses in all of pediatric oncology. A child in the high-risk group faces one of the worst. The overall average, near 80%, describes neither of them.

Roughly how are children distributed? The NCI reports that about 40% of newly diagnosed children have localized disease and about 50% have metastatic disease at diagnosis, with the remainder being the special infant pattern discussed below. Not every child with metastatic disease lands in the high-risk group, because infants with spread to certain sites are often treated as intermediate or even low risk. Age, once again, is doing much of the work.

Why doctors talk about risk groups more than stages

Most cancers are staged the way a map is drawn: where is the tumor, how big is it, has it reached lymph nodes, has it traveled. Neuroblastoma is staged too, using either the older International Neuroblastoma Staging System (stages 1 through 4, plus 4S) based on what surgeons find, or the newer International Neuroblastoma Risk Group system (stages L1, L2, M, and MS) based on imaging before surgery. The NCI describes both systems in detail.

Stage alone, however, misleads. Consider two children, both with tumors confined to the abdomen and no spread. One is 8 months old with favorable tumor biology; the other is 4 years old with a tumor carrying extra copies of the MYCN gene. Same stage, radically different diseases. The second child is treated as high risk, with an outlook closer to a stage 4 case than to the infant beside them.

That is why risk grouping was built. It layers stage together with age, MYCN status, tumor histology, DNA content of the tumor cells, and, in newer systems, loss of a segment of chromosome 11. The result is a classification that tracks actual outcomes closely enough for doctors to decide how intensively to treat.

For a parent reading a report, the practical translation is this: the stage tells you where the disease is; the risk group tells you what the disease is likely to do. If a clinician has only shared a stage, asking for the risk group and what features placed the child there is a reasonable and useful question.

How age changes the outlook, and the strange case of stage 4S

Few facts in cancer medicine are as counterintuitive as this one: an infant with neuroblastoma spread to the liver, skin, and bone marrow often does better than a toddler with a tumor confined to one spot. The NCI reports survival above 90% for infants with the pattern designated stage 4S (or MS in the newer system), and many of these babies receive little or no treatment.

The reason is regression. Neuroblastoma cells in very young infants frequently retain the developmental program that tells immature nerve cells to mature or self-destruct. Over weeks to months, tumors that looked alarming on a scan simply fade. Doctors monitor closely and step in only if a rapidly enlarging liver threatens breathing or feeding, which can happen in the youngest infants.

This biology is also why age 18 months functions as a dividing line in risk grouping. The NCI notes that children younger than 18 months with metastatic disease are generally placed in lower risk groups than older children with the same spread, provided the tumor biology is favorable. Past that age, spontaneous regression becomes rare and the same anatomic picture signals aggressive disease.

Regression is also the reason infant screening failed. Large studies in Germany and Quebec tested babies’ urine for tumor breakdown products, found many more neuroblastomas, and did not reduce deaths, according to the NCI. The extra tumors found were overwhelmingly the kind that would have disappeared on their own. Finding them earlier changed nothing except the number of families who went through a cancer diagnosis.

Can a child recover from stage 4 neuroblastoma?

Yes, and many do, though the path is long and the odds depend on age and biology as much as on the stage itself. Stage 4 means the tumor has spread to distant sites such as bone, bone marrow, or distant lymph nodes. In a child older than 18 months, that almost always means high-risk treatment, and the NCI places long-term survival for high-risk disease at roughly half of children. In an infant with favorable biology, the same stage may be treated as intermediate risk with a far better outlook.

For the high-risk group, treatment unfolds in phases that typically stretch over 12 to 18 months. Induction chemotherapy comes first, aiming to shrink the primary tumor and clear metastatic sites. Surgery follows to remove as much of the primary tumor as can be safely taken. Consolidation then uses very high doses of chemotherapy followed by return of the child’s own previously collected blood stem cells to rebuild the marrow, often done twice in sequence, along with radiation to the tumor bed. A final maintenance phase uses an antibody that targets a molecule called GD2 on the surface of neuroblastoma cells, marking them for the child’s own immune system, combined with a medicine that pushes remaining tumor cells to mature. The NCI attributes a meaningful share of the improvement in high-risk survival to that immunotherapy phase.

Recovery is real, but so is the cost. Children who complete this regimen face months in and out of the hospital and a list of possible long-term effects covered later in this article. Families weighing what these statistics mean should hear both halves of that sentence from their care team, not just the percentage.

What does tumor biology tell doctors that a scan cannot?

Two children can have tumors of identical size in identical places and completely different prognoses. The difference sits inside the cells. A pathologist and a genetics laboratory examine the tumor tissue for several features, and each one shifts the risk group.

The most influential is MYCN amplification. Normal cells carry two copies of this gene; some neuroblastomas carry dozens or hundreds. The NCI reports that MYCN amplification is present in about 20 to 25% of neuroblastomas overall and places a child in the high-risk group regardless of age or stage, because amplified tumors grow fast and resist maturing. This single finding can move a child with localized disease from the low-risk column to the high-risk one.

Histology matters too. Under the microscope, pathologists grade how mature the cells look and how many are dividing. Tumors with more mature-looking cells and fewer dividing cells are labeled favorable histology; the reverse is unfavorable, and the NCI notes the classification is adjusted for the child’s age.

DNA content is a third clue, and here the finding is backwards from what intuition suggests. Tumor cells with more than the normal amount of DNA, called hyperdiploid, are associated with better outcomes in infants, while tumors with a normal DNA amount tend to behave worse. The NCI also lists loss of part of chromosome 11q as an unfavorable marker used in newer risk classifications.

Newer testing looks at mutations in a gene called ALK, found in a minority of tumors and more common in the rare inherited form. The NCI notes these mutations are being studied as a target for treatment in clinical trials, though how much they change prognosis on their own is still being defined.

Is neuroblastoma the deadliest childhood cancer?

Not by the measure most people mean, but it is disproportionately deadly for its size. Neuroblastoma accounts for about 6% of childhood cancers yet roughly 15% of childhood cancer deaths, according to figures cited by the NCI. That mismatch is almost entirely the high-risk group at work. Low-risk and intermediate-risk children survive at rates matching or exceeding the best-treated childhood leukemias; high-risk children pull the average sharply down.

Which cancers are more lethal? Certain brain tumors that arise in the brainstem have near-zero long-term survival and are widely regarded as the hardest childhood cancers to treat. Some rare sarcomas and relapsed leukemias also carry poorer odds than neuroblastoma taken as a whole. Ranking cancers this way is a blunt exercise, though. A child in the high-risk neuroblastoma group faces odds comparable to those difficult diagnoses; a child in the low-risk group does not belong in the same sentence.

What the deadliest label obscures is trajectory. The NCI describes steady gains in high-risk survival since the 1990s as treatment intensified and immunotherapy was added, with more recent cohorts reporting figures above the roughly 50% quoted from older registries. The disease has not become gentle. The medicine has become better at meeting it. That distinction matters for a family reading statistics collected from children diagnosed years before their own.

What are the early symptoms of neuroblastoma?

Early neuroblastoma is quiet. Many tumors are found only when a pediatrician feels an unexpected firmness in a toddler’s belly during a routine exam, or when a scan ordered for something else picks up a mass. Once symptoms appear, they depend almost entirely on where the tumor sits and where it has spread, which is why the picture varies so widely.

The Mayo Clinic and Cleveland Clinic describe common presentations that include:

• A swollen, firm abdomen, sometimes with a lump a parent can feel, along with reduced appetite or constipation
• Bone pain, limping, or refusing to walk in a child who was walking, reflecting spread to bone
• Dark bruising around the eyes or bulging of one eye, from tumor deposits behind the eye socket
• Persistent fever, irritability, paleness, or weight loss without a clear cause
• A painless lump in the neck, occasionally with a drooping eyelid and small pupil on the same side
• Weakness or numbness in the legs or trouble with bladder control, when a tumor presses on the spinal cord
• Wheezing or difficulty breathing from a tumor in the chest

Rarer signs are striking enough to have their own names. Some children develop rapid, jerking eye movements and unsteady balance, a condition caused by the immune system reacting to the tumor; the NCI notes these children often have smaller, more favorable tumors. Others have persistent watery diarrhea because the tumor secretes a hormone. In infants, bluish skin nodules can appear.

Every item on that list overlaps with ordinary childhood illness. Bone pain looks like growing pains; a swollen belly looks like constipation. The pattern that should raise concern is persistence, combination, and a child who is simply not themselves for weeks rather than days.

When to see a doctor: red-flag signs that should not wait

Most children with a swollen tummy or a sore leg have something ordinary. Still, a small number of findings deserve a same-week appointment, and a few deserve a same-day one.

Book a prompt visit if a child has a lump or firmness in the abdomen, neck, or chest that does not go away; unexplained fever or weight loss lasting more than a couple of weeks; bone pain or limping that persists without an injury; or bruising or swelling around the eyes without a clear cause. A pediatrician can examine the child, and if anything is uncertain, ultrasound is a quick, radiation-free first step that the Mayo Clinic lists among the initial tests.

Seek emergency care the same day if a child develops sudden weakness in the legs, loses the ability to walk, cannot control bladder or bowel, or has severe or rapidly worsening trouble breathing. Spinal cord compression from a tumor beside the spine is treatable, but the NCI stresses that outcomes for nerve function depend on how quickly pressure is relieved. Rapid abdominal swelling in a young infant that seems to interfere with feeding or breathing also warrants urgent assessment.

One reassurance belongs here. Bringing a child in for these signs almost always ends with a benign explanation. The point of listing them is not to alarm parents but to make the rare serious case easier to catch at a stage when treatment is simplest. Diagnosis itself involves imaging, urine tests for tumor breakdown products, and eventually a biopsy and bone marrow sampling, steps that a specialist team will walk through if a tumor is suspected.

How treatment is matched to risk, and what actually moved the numbers

Neuroblastoma treatment is deliberately unequal. Giving every child the most intensive regimen would harm the many to help the few; giving every child the gentlest would fail those with aggressive disease. Risk grouping is the tool that lets doctors calibrate.

Low-risk children may have surgery alone, and some infants with small adrenal tumors or the 4S pattern are simply observed with regular scans, an approach the NCI describes as appropriate when biology is favorable. Intermediate-risk children usually receive a moderate course of chemotherapy, typically a few months, followed by surgery, with the number of cycles adjusted to how the tumor responds. High-risk children receive the multi-phase regimen described earlier, running well over a year.

Which changes moved survival most? The NCI credits several. Intensifying chemotherapy and adding high-dose consolidation with stem cell rescue improved high-risk outcomes in the 1990s and early 2000s. Adding a second consolidation cycle in sequence produced a further gain in a large cooperative trial. The clearest single step was immunotherapy against GD2, which in a randomized trial improved event-free survival compared with standard maintenance alone. Meanwhile, for lower-risk children, the important shift ran the other way: trials showed that reducing or eliminating chemotherapy did not lower survival, sparing thousands of children unnecessary toxicity.

Every one of these changes came from cooperative group clinical trials enrolling children across many centers. That is why oncologists so often offer trial participation for high-risk and relapsed disease. It is not experimentation on a child as a last resort; it is the mechanism by which the numbers in this article have risen at all.

What happens if neuroblastoma comes back?

Relapse is the shadow over high-risk statistics. The NCI reports that roughly half of children with high-risk neuroblastoma who achieve remission will see the disease return, most often within the first two to three years after treatment ends. For low-risk and intermediate-risk children, recurrence is uncommon and, when it happens, is frequently still curable with more treatment.

Recurrent high-risk disease is genuinely difficult. The NCI describes long-term survival after relapse of high-risk neuroblastoma as poor, and most treatment at that point aims to control disease, extend life, and preserve quality of life rather than to cure. Options include different chemotherapy combinations, repeat immunotherapy, radiation to painful sites, and a targeted form of radiation delivered by a tracer that neuroblastoma cells absorb. Clinical trials testing new drugs, including ones aimed at ALK-mutated tumors, are a central part of care for relapsed disease.

Two details give the picture more nuance. First, where and how the disease returns matters. A single site found on routine surveillance behaves differently from widespread marrow involvement with symptoms. Second, the timing matters: recurrence years after treatment tends to carry a somewhat better outlook than recurrence during or shortly after therapy.

For families, the practical consequence is surveillance. Children treated for high-risk disease have scheduled imaging, urine testing, and sometimes bone marrow checks for years. Those appointments are anxious days, and there is no way to make them otherwise. What they provide is the earliest possible signal when something needs attention, and the reassurance, appointment after appointment, when nothing does.

Life after neuroblastoma: late effects and long-term follow-up

Surviving neuroblastoma is the goal, but survival statistics stop at the moment they are measured, and childhood continues long past it. Children treated for low-risk disease usually grow up with few or no lasting effects. Children who have gone through high-risk therapy carry a longer list, and honest counseling includes it.

The Cleveland Clinic and NCI describe late effects that can include hearing loss from certain chemotherapy drugs, which is common enough that hearing tests are routine before and after treatment; slowed growth or thyroid problems from radiation; effects on fertility from high-dose chemotherapy, which is why fertility preservation is discussed for older children where feasible; dental problems from treatment during tooth development; and a small increased risk of a second cancer years later. Kidney function, heart function, and learning are also monitored, particularly in children treated as infants.

None of this is a reason to soften treatment for high-risk disease; the alternative is worse. It is a reason survivorship care exists as its own discipline. The NCI recommends that childhood cancer survivors have lifelong follow-up tailored to the therapy they received, and most pediatric cancer programs run dedicated survivorship clinics for exactly this purpose.

A final thought on reading these numbers. A survival rate is a portrait of many children painted from behind, describing what happened to a group already treated. The child in front of a family is one person, diagnosed today, with a specific age, a specific tumor biology, and access to treatment the older data never saw. Ask the care team which risk group applies and what evidence shaped that placement. That conversation, more than any percentage, is where the real answer lives.

Frequently asked questions

Is neuroblastoma a curable cancer?

For most children, yes. The National Cancer Institute reports five-year survival above 95% for low-risk and roughly 90 to 95% for intermediate-risk neuroblastoma, and many of these children are treated with surgery alone or brief chemotherapy. High-risk neuroblastoma is harder, with long-term survival near half of children despite intensive treatment. Doctors usually speak of remission and years of follow-up before using the word cured for high-risk disease.

What is the neuroblastoma survival rate for stage 4?

It depends on the child’s age and the tumor’s biology more than on the stage label. Children older than 18 months with stage 4 disease are almost always high risk, with five-year survival around 50% according to the NCI and Cleveland Clinic. Infants younger than 18 months with stage 4 disease and favorable biology are often treated as intermediate risk and have substantially better outcomes.

Can a child recover from stage 4 neuroblastoma?

Yes, and many do. High-risk treatment runs 12 to 18 months and includes induction chemotherapy, surgery, high-dose chemotherapy with the child’s own stem cells returned afterward, radiation, and immunotherapy targeting the GD2 molecule on tumor cells. The NCI credits that immunotherapy phase with a meaningful share of the improvement in high-risk survival. Recovery carries real long-term effects, which survivorship clinics monitor for years.

Is neuroblastoma the deadliest childhood cancer?

Not overall, but it is disproportionately deadly for its size. Neuroblastoma is about 6% of childhood cancers yet roughly 15% of childhood cancer deaths, per figures cited by the NCI. That gap is driven almost entirely by the high-risk group. Certain brainstem tumors carry far worse odds than neuroblastoma taken as a whole, while low-risk neuroblastoma has among the best outcomes in pediatric oncology.

What are the early symptoms of neuroblastoma?

Early neuroblastoma often causes no symptoms and is found when a doctor feels an abdominal mass. When symptoms appear, the Mayo Clinic and Cleveland Clinic list a swollen or firm belly, bone pain or limping, dark bruising around the eyes, persistent fever, weight loss, a painless neck lump, or leg weakness. Because each overlaps with ordinary illness, persistence over weeks and several signs together are what should prompt a visit.

What is stage 4S neuroblastoma and why is survival so high?

Stage 4S, called MS in the newer system, describes infants under 12 to 18 months whose tumor has spread to the liver, skin, or a small amount of bone marrow but not to bone. The NCI reports survival above 90%, because these tumors frequently regress on their own as the immature cells finish maturing or die off. Many infants are observed rather than treated, with intervention only if a rapidly enlarging liver threatens breathing.

Why does MYCN amplification matter so much?

MYCN is a gene that drives cell growth, and some neuroblastomas carry dozens or hundreds of extra copies instead of the normal two. The NCI reports amplification in about 20 to 25% of tumors and treats it as an automatic high-risk marker regardless of stage or age, because amplified tumors grow quickly and resist the maturation that makes other neuroblastomas regress. It can move a localized tumor into the high-risk group.

What happens if neuroblastoma relapses?

It depends on the original risk group. Recurrence after low-risk or intermediate-risk treatment is uncommon and often still curable. After high-risk treatment, the NCI reports that roughly half of children who reach remission relapse, usually within two to three years, and long-term survival after that is poor. Care then focuses on controlling disease and quality of life, often through clinical trials of newer agents.

Can neuroblastoma be detected by screening babies?

It can be detected, but screening does not save lives. Large trials in Germany and Quebec tested infants’ urine for tumor breakdown products, found many more neuroblastomas, and did not reduce deaths, according to the NCI. The extra tumors were overwhelmingly the type that regresses on its own, so screening exposed more families to a cancer diagnosis without changing outcomes. Routine infant screening is therefore not recommended.

What long-term effects do neuroblastoma survivors face?

Children treated for low-risk disease usually have few lasting effects. After high-risk therapy, the Cleveland Clinic and NCI describe possible hearing loss, slowed growth, thyroid problems, effects on fertility, dental issues, and a small increased risk of a second cancer years later. Heart, kidney, and learning are also monitored. Lifelong follow-up in a survivorship clinic is recommended and tailored to the specific treatment a child received.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.